{"id":"NCT00725491","sponsor":"Organon and Co","briefTitle":"A Study to Assess the Efficacy and Safety of Ganirelix (Orgalutran®) Treatment in Chinese Women Undergoing Controlled Ovarian Stimulation for in Vitro Fertilization (IVF) or Intra Cytoplasmatic Sperm Injection (ICSI) (Study 38651)(P05703)","officialTitle":"A Phase III, Multi-center, Open-label, Randomized Study to Assess the Efficacy and Safety of Org 37462 Treatment in Chinese Women Undergoing Controlled Ovarian Stimulation for IVF or ICSI, Using a Long Protocol of Triptorelin as a Reference Treatment.","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2007-05","primaryCompletion":"2008-12","completion":"2008-12","firstPosted":"2008-07-30","resultsPosted":"2010-01-22","lastUpdate":"2022-02-03"},"enrollment":259,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Controlled Ovarian Stimulation"],"interventions":[{"type":"DRUG","name":"ganirelix","otherNames":["Orgalutran®","Org 37462"]},{"type":"DRUG","name":"triptorelin","otherNames":["Decapeptyl"]}],"arms":[{"label":"1","type":"EXPERIMENTAL"},{"label":"2","type":"ACTIVE_COMPARATOR"}],"summary":"The primary purpose of this study is to assess that ganirelix is safe and well-tolerated in Chinese women and that a controlled ovarian stimulation (COS) protocol combining recombinant follicle stimulating hormone (recFSH) with ganirelix is efficient in Chinese women undergoing COS for in vitro fertilization (IVF) or intra cytoplasmatic sperm injection (ICSI).","primaryOutcome":{"measure":"The Amount of International Units (IU) of Recombinant Follicle Stimulating Hormone (recFSH) Needed in a Controlled Ovarian Stimulation (COS) Cycle up to the First Day the Human Chorionic Gonadotropin (hCG) Criterion is Met.","timeFrame":"At completion of ovarian stimulation; maximally after 18 days of recFSH administration.","effectByArm":[{"arm":"Ganirelix","deltaMin":1272,"sd":265.8},{"arm":"Triptorelin","deltaMin":1415.6,"sd":355.6}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.001"}]},"eligibility":{"minAge":"18 Years","sex":"FEMALE","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":18},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":["22429192"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":4,"n":112},"commonTop":["Nausea","Vomiting","Antepartum haemorrhage"]}}